Literature DB >> 33603125

A retrospective study assessing the acceleration effect of type I Helicobacter pylori infection on the progress of atrophic gastritis.

Weidong Liu1, Junjie Tian2, Wenjia Hui1, Wenjie Kong1, Yan Feng1, Junqiang Si3, Feng Gao4.   

Abstract

Based on the antibody typing classification, Helicobacter pylori infection can be divided into type I H. pylori infection and type II H. pylori infection. To observe the effects of different H. pylori infection types on the distribution of histopathological characteristics and the levels of three items of serum gastric function (PG I, PG II, G-17). 1175 cases from October 2018 to February 2020 were collected with ratio 1:2. All patients were performed with 14C-Urea breath test (14C-UBT), H. pylori antibody typing classification, three items of serum gastric function detection, painless gastroscopy, pathological examination, etc. According to H. pylori antibody typing classification, patients were divided into three groups: type I H. pylori infection group, type II H. pylori infection group and control group. Significant difference existed among type I H. pylori infection group, type II H. pylori infection group and control group in inflammation and activity (χ2 = 165.43, 354.88, P all < 0.01). The proportion of three groups in OLGA staging had statistic difference (χ2 = 67.99, P all < 0.01); Compared with type II H. pylori infection group and control group, the level of pepsinogen I, pepsinogen II, gastrin17 in type I H. pylori infection group increased, and PG I/PG II ratio (PG I/PG II ratio, PGR) decreased, which was statistically significant (χ2 = 35.08, 166.24, 134.21, 141.19; P all < 0.01). Type I H. pylori infection worsened the severity of gastric mucosal inflammation and activity. H. pylori infection was prone to induce atrophy of gastric mucosa, while type I H. pylori infection played a key role in promoting the progress of atrophic gastritis and affected the level of serum gastric function. The study indicated that the eradication of H. pylori should be treated individually.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33603125      PMCID: PMC7892840          DOI: 10.1038/s41598-021-83647-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  34 in total

1.  Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection.

Authors:  Wen Zhong Liu; Yong Xie; Hong Lu; Hong Cheng; Zhi Rong Zeng; Li Ya Zhou; Ye Chen; Jiang Bin Wang; Yi Qi Du; Nong Hua Lu
Journal:  Helicobacter       Date:  2018-03-07       Impact factor: 5.753

2.  Multiplex serology of Helicobacter pylori antigens in detection of current infection and atrophic gastritis - A simple and cost-efficient method.

Authors:  Ebrahim Shafaie; Samaneh Saberi; Maryam Esmaeili; Zeynab Karimi; Saeed Najafi; Mohammad Tashakoripoor; Afshin Abdirad; Mahmoud Eshagh Hosseini; Mohammad Ali Mohagheghi; Vahid Khalaj; Marjan Mohammadi
Journal:  Microb Pathog       Date:  2018-04-14       Impact factor: 3.738

3.  Implications of corpus gastritis, atrophy and cyclooxygenase in the development of gastric erosions after curing Helicobacter pylori infection.

Authors:  K Miyake; A Tatsuguchi; K Suzuki; N Ueki; Y Shinji; M Kusunoki; T Iizumi; T Hiratsuka; H Nishigaki; S Futagami; K Wada; T Tsukui; C Sakamoto
Journal:  Dig Liver Dis       Date:  2005-03-02       Impact factor: 4.088

4.  Pepsinogen test for the evaluation of precancerous changes in gastric mucosa: a population-based study.

Authors:  Olga Sjomina; Jelizaveta Pavlova; Ilva Daugule; Pavel Janovic; Ilze Kikuste; Aigars Vanags; Ivars Tolmanis; Dace Rudzite; Inese Polaka; Ilona Kojalo; Inta Liepniece-Karele; Sergejs Isajevs; Daiga Santare; Valdis Pirags; Jelena Pahomova; Vilnis Dzerve; Lilian Tzivian; Andrejs Erglis; Marcis Leja
Journal:  J Gastrointestin Liver Dis       Date:  2018-03       Impact factor: 2.008

5.  Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015.

Authors:  Rocco Maurizio Zagari; Marco Romano; Veronica Ojetti; Reinhold Stockbrugger; Sergio Gullini; Bruno Annibale; Fabio Farinati; Enzo Ierardi; Giovanni Maconi; Massimo Rugge; Carlo Calabrese; Francesco Di Mario; Francesco Luzza; Stefano Pretolani; Antonella Savio; Giovanni Gasbarrini; Michele Caselli
Journal:  Dig Liver Dis       Date:  2015-07-06       Impact factor: 4.088

6.  Analysis of the relationship between invasive capability of Helicobacter pylori and gastroduodenal diseases.

Authors:  Xiaoyan Zhang; Jie Zhang; Yunbin Lin; Kai Xu; Neng Li; Hao Chen; Feifei She
Journal:  J Med Microbiol       Date:  2015-03-09       Impact factor: 2.472

Review 7.  A current clinical overview of atrophic gastritis.

Authors:  Bruno Annibale; Gianluca Esposito; Edith Lahner
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-01-24       Impact factor: 3.869

8.  Performance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform.

Authors:  Angela Filomena; Anna Guenther; Hannes Planatscher; Francois Topin; Joseph She; Luca Formichella; Laurent Terradot; Markus Gerhard; Thomas O Joos; Hannelore Meyer; Nicole Schneiderhan-Marra
Journal:  Proteomes       Date:  2017-10-03

9.  Low PG I/II ratio as a marker of atrophic gastritis: Association with nutritional and metabolic status in healthy people.

Authors:  Weiwei Su; Bin Zhou; Guangming Qin; Zhihao Chen; Xiaoge Geng; Xiaojun Chen; Wensheng Pan
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

10.  Helicobacter pylori CagA Protein Negatively Regulates Autophagy and Promotes Inflammatory Response via c-Met-PI3K/Akt-mTOR Signaling Pathway.

Authors:  Na Li; Bin Tang; Yin-Ping Jia; Pan Zhu; Yuan Zhuang; Yao Fang; Qian Li; Kun Wang; Wei-Jun Zhang; Gang Guo; Tong-Jian Wang; You-Jun Feng; Bin Qiao; Xu-Hu Mao; Quan-Ming Zou
Journal:  Front Cell Infect Microbiol       Date:  2017-09-21       Impact factor: 5.293

View more
  1 in total

Review 1.  The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications.

Authors:  Amir Hossein Miri; Mojtaba Kamankesh; Antoni Llopis-Lorente; Chenguang Liu; Matthias G Wacker; Ismaeil Haririan; Hamid Asadzadeh Aghdaei; Michael R Hamblin; Abbas Yadegar; Mazda Rad-Malekshahi; Mohammad Reza Zali
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.